Cargando…

PARP Inhibitors in Advanced Prostate Cancer in Tumors with DNA Damage Signatures

SIMPLE SUMMARY: This review paper seeks to summarize the current literature on the role of PARP Inhibitors in Advanced Prostate Cancer in tumors with defects in genes associated with DNA damage repair. It will give particular attention to the role of PARPi in tumors with non-BRCA DNA damage repair g...

Descripción completa

Detalles Bibliográficos
Autores principales:	McNevin, Ciara S., Cadoo, Karen, Baird, Anne-Marie, Finn, Stephen P., McDermott, Ray
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9564112/ https://www.ncbi.nlm.nih.gov/pubmed/36230674 http://dx.doi.org/10.3390/cancers14194751

Ejemplares similares

Pathogenic BRCA Variants as Biomarkers for Risk in Prostate Cancer
por: McNevin, Ciara S., et al.
Publicado: (2021)

Diagnostic Strategies for Treatment Selection in Advanced Prostate Cancer
por: McNevin, Ciara S., et al.
Publicado: (2021)

Differential CircRNA Expression Signatures May Serve as Potential Novel Biomarkers in Prostate Cancer
por: Greene, John, et al.
Publicado: (2021)

hsa_circ_0001275 Is One of a Number of circRNAs Dysregulated in Enzalutamide Resistant Prostate Cancer and Confers Enzalutamide Resistance In Vitro
por: Lim, Marvin C. J., et al.
Publicado: (2021)

Advances in PARP Inhibitors for Prostate Cancer
por: Tisseverasinghe, Steven, et al.
Publicado: (2023)

PARP inhibitors trap PARP2 and alter the mode of recruitment of PARP2 at DNA damage sites
por: Lin, Xiaohui, et al.
Publicado: (2022)

Deep Learning of Histopathological Features for the Prediction of Tumour Molecular Genetics
por: Murchan, Pierre, et al.
Publicado: (2021)

Clinical PARP inhibitors do not abrogate PARP1 exchange at DNA damage sites in vivo
por: Shao, Zhengping, et al.
Publicado: (2020)

Carcinogenesis in prostate cancer: The role of long non-coding RNAs
por: Aird, John, et al.
Publicado: (2018)

Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing’s Sarcoma
por: Gill, Sonja J., et al.
Publicado: (2015)

Longitudinal analysis of individual cfDNA methylome patterns in metastatic prostate cancer
por: Silva, Romina, et al.
Publicado: (2021)

PARP Power: A Structural Perspective on PARP1, PARP2, and PARP3 in DNA Damage Repair and Nucleosome Remodelling
por: van Beek, Lotte, et al.
Publicado: (2021)

PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers
por: Teyssonneau, Diego, et al.
Publicado: (2022)

Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage response
por: Francica, Paola, et al.
Publicado: (2018)

NADP(+) is an endogenous PARP inhibitor in DNA damage response and tumor suppression
por: Bian, Chunjing, et al.
Publicado: (2019)

PARP1 inhibitors trigger innate immunity via PARP1 trapping-induced DNA damage response
por: Kim, Chiho, et al.
Publicado: (2020)

PARP inhibitor combinations in prostate cancer
por: Pezaro, Carmel
Publicado: (2020)

PARP Inhibitors in Prostate and Urothelial Cancers
por: Garje, Rohan, et al.
Publicado: (2020)

PARP inhibitors in metastatic prostate cancer
por: Taylor, Amy K., et al.
Publicado: (2023)

Advances and perspectives of PARP inhibitors
por: Yi, Ming, et al.
Publicado: (2019)

Strategic Combination of DNA-Damaging Agent and PARP Inhibitor Results in Enhanced Cytotoxicity
por: Horton, Julie K., et al.
Publicado: (2013)

The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma
por: Park, Hye Jeong, et al.
Publicado: (2018)

Introducing the 3(rd) Annual PARP and DNA Damage Response Inhibitors Summit
Publicado: (2020)

Advances in the use of PARP inhibitor therapy for breast cancer
por: McCann, Kelly E, et al.
Publicado: (2018)

The Role of PARP Inhibitors in the Treatment of Prostate Cancer: Recent Advances in Clinical Trials
por: Xia, Mingyue, et al.
Publicado: (2021)

PARP-1 inhibitors enhance the chemosensitivity of leukemia cells by attenuating NF- кB pathway activity and DNA damage response induced by Idarubicin : PARP-1 inhibitors attenuate DNA damage response
por: Ke, Bo, et al.
Publicado: (2021)

RNAs as Candidate Diagnostic and Prognostic Markers of Prostate Cancer—From Cell Line Models to Liquid Biopsies
por: Lim, Marvin C. J., et al.
Publicado: (2018)

Prostate cancer and PARP inhibitors: progress and challenges
por: Teyssonneau, Diego, et al.
Publicado: (2021)

Clinical PARP inhibitors allosterically induce PARP2 retention on DNA
por: Langelier, Marie-France, et al.
Publicado: (2023)

A PARP1-related prognostic signature constructing and PARP-1 inhibitors screening for glioma
por: Li, Hui, et al.
Publicado: (2022)

Forensic Autosomal Short Tandem Repeats and Their Potential Association With Phenotype
por: Wyner, Nicole, et al.
Publicado: (2020)

PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells
por: Yin, Linglong, et al.
Publicado: (2018)

PARP inhibitor re-sensitizes Adriamycin resistant leukemia cells through DNA damage and apoptosis
por: Wu, Jie, et al.
Publicado: (2019)

LKB1 is a DNA damage response protein that regulates cellular sensitivity to PARP inhibitors
por: Wang, Yi-Shu, et al.
Publicado: (2016)

The PARP1 Inhibitor Niraparib Represses DNA Damage Repair and Synergizes with Temozolomide for Antimyeloma Effects
por: Shen, Hong-Yuan, et al.
Publicado: (2022)

PARP Inhibitors in Metastatic Prostate Cancer: Evidence to Date
por: Nizialek, Emily, et al.
Publicado: (2020)

Advances in using PARP inhibitors to treat cancer
por: Kummar, Shivaani, et al.
Publicado: (2012)

Advancements and Obstacles of PARP Inhibitors in Gastric Cancer
por: Chen, Hongjie, et al.
Publicado: (2023)

Inhibition of DNA damage repair by artificial activation of PARP with siDNA
por: Croset, Amelie, et al.
Publicado: (2013)

Baseline risk of hematologic malignancy at initiation of frontline PARP inhibitor maintenance for BRCA1/2-associated ovarian cancer
por: Navitski, Anastasia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4puqii6pitddbr3m9g3upjvmvp